Real-World Data Show 76% Slower Alzheimer's Progression on LEQEMBI
BIIB sits 55% above its 52-week low of $160.365 on light trading volume (0.2× avg).
Summary
Three-year real-world data from 560 patients across 13 U.S. sites found a 76% lower rate of progression to moderate or severe Alzheimer's dementia with LEQEMBI versus a matched natural history cohort. A separate meta-analysis covered roughly 5,000 patients, though the release gives no quantified outcome for it. This is retrospective, non-randomized evidence for an already-marketed drug, not a new approval or controlled-trial result, so it supports the commercial case rather than resetting it. Safety findings were consistent with ALZ-NET and the U.S. prescribing information, meaning no new safety signal. The data lands after a run of positive LEQEMBI news, including Japan's September approval of the subcutaneous autoinjector and Canada's August reimbursement recommendation.
At the time of this announcement, BIIB was trading at $249.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $36.9B. The 52-week trading range was $160.36 to $261.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.